Neuropsychiatric adverse drug reactions with oral tyrosine kinase inhibitors in metastatic colorectal cancer: an analysis from the FDA Adverse Event Reporting System

Neuropsychiatric adverse drug reactions with oral tyrosine kinase inhibitors in metastatic colorectal cancer: an analysis from the FDA Adverse Event Reporting System

IntroductionNew oral tyrosine kinase inhibitors (TKIs) are approved for metastatic colorectal cancer (mCRC). The aim of this study was to assess the neuropsychiatric adverse drug reactions (ADRs) of these drugs reported in the FDA Adverse Event Reporting System (FAERS) database.MethodsAll reports wi...

Full description

Bibliographic Details
Main Authors: Maria Antonietta Barbieri, Giulia Russo, Emanuela Elisa Sorbara, Giuseppe Cicala, Tindara Franchina, Mariacarmela Santarpia, Desirèe Speranza, Edoardo Spina, Nicola Silvestris
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-10-01
Series:Frontiers in Oncology
Subjects:
adverse drug reactions
colorectal cancer
encorafenib
neuropsychiatric disorders
oral tyrosine kinase inhibitors
regorafenib
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1268672/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1268672/full

Similar Items